Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma

References

• Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure:comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503–2512.
   PubMed Web of Science ®Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1:769–783.
   PubMed Web of Science ®Google Scholar
• Lopez T, Hanahan D. Elevated levels of the IGF-I receptor convey invasion and metastatic capability in a mouse model of pancreatic islet tumourigenesis. Cancer Cell 2002;1:339–353.
   PubMed Web of Science ®Google Scholar
• Mauro L, Bartucci M, Morelli C, et al. IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem 2001;276:39892–39897.
   PubMed Web of Science ®Google Scholar
• Van Golen CM, Schwab TS, Kim B, et al. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res 2006;66:6570–6578.
   PubMed Web of Science ®Google Scholar
• Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123:1191–1204.
   PubMed Web of Science ®Google Scholar
• Burfeind P, Chernicky CL, Rininsland F, et al. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93:7263–7268.
   PubMed Web of Science ®Google Scholar
• Dunn SE, Ehrlich M, Sharp NJ, et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998;58:3353–3361.
   PubMed Web of Science ®Google Scholar
• Hongo A, Kuramoto H, Nakamura Y, et al. Antitumor effects of a soluble insulin-like growth factor I receptor in human ovarian cancer cells: advantage of recombinant protein administration in vivo. Cancer Res 2003;63:7834–7839.
   Google Scholar
• Lee CT, Park KH, Adachi Y, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 2003;10:57–63.
   PubMed Web of Science ®Google Scholar
• Yin S, Girnita A, Stromberg T, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 2010;12:19–27.
   PubMed Web of Science ®Google Scholar
• Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R mediated growth in hematopoietic cells. Leukemia 2006;20:1254–1260.
   PubMed Web of Science ®Google Scholar
• Strömberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006;107:669–678.
   PubMed Web of Science ®Google Scholar
• Menu E, Jernberg-Wiklund H, Strömberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006;107: 655–660.
   PubMed Web of Science ®Google Scholar
• Shi P, Lai R, Lin Q, et al. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood 2009;114:360–370.
   PubMed Web of Science ®Google Scholar
• Shi P, Chandra J, Sun X, et al. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med 2010;14:1777–1792.
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Tabellini G, Bortul R, et al. The insulin like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007;21:886–896.
   PubMed Web of Science ®Google Scholar
• Wahner Hendrickson AE, Haluska P, Schneider PA, et al. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 2009;69: 7635–7643.
   PubMed Web of Science ®Google Scholar
• Vishwamitra D, Shi P, Wilson D, et al. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. Haematologica 2011;96:871–880.
   PubMed Web of Science ®Google Scholar
• Shi B, Vishwamitra D, Granda JG, et al. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia 2013;15:669–683.
   PubMed Web of Science ®Google Scholar
• Girnita A, Girnita L, Del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236–242.
   PubMed Web of Science ®Google Scholar
• Vasilcanu D, Girnita A, Girnita L, et al. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004;23:7854–7862.
   PubMed Web of Science ®Google Scholar
• Ohshima-Hosoyama S , Hosoyama T, Nelon LD, et al. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma, Biochem Bioph Res Commun 2010;399:727–732.
   PubMed Web of Science ®Google Scholar
• Ekman S, Frödin J, Harmenberg J, et al. Clinical phase I study with an insulin-like growth factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 2011;50:441–447.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Kantarjian HM. Lymphoblastic lymphoma. Hematol Oncol Clin North Am 2001;15:51–95.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Chan JKC. T lymphoblastic leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 176–178.
   Google Scholar
• Lee PD, Rosenfeld RG, Hintz RL, et al. Characterization of insulin, insulin-like growth factors I and II, and growth hormone receptors on human leukemic lymphoblasts. J Clin Endocrinol Metab 1986; 62:28–35.
   PubMed Web of Science ®Google Scholar
• Baier TG, Ludwig WD, Schönberg D, et al. Characterisation of insulin-like growth factor I receptors of human acute lymphoblastic leukaemia (ALL) cell lines and primary ALL cells. Eur J Cancer 1992;28A:1105–1110.
   PubMed Web of Science ®Google Scholar
• Medyouf H, Gusscott S, Wang H, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med 2011;208:1809–1822.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
   PubMed Web of Science ®Google Scholar
• Bergman AC, Benjamin T, Alaiya A, et al. Identification of gel separated tumor marker proteins by mass spectrometry. Electrophoresis 2000;21:679–686.
   PubMed Web of Science ®Google Scholar
• Nauseef WM, McCormick SJ, Clark RA. Calreticulin functions as a molecular chaperone in the biosynthesis of myeloperoxidase. J Biol Chem 1995;270:4741–4747.
   PubMed Web of Science ®Google Scholar
• Holaska JM, Black BE, Love DC, et al. Calreticulin is a receptor for nuclear export. J Cell Biol 2001;152:127–140.
   PubMed Web of Science ®Google Scholar
• Tarr JM, Young PJ, Morse R, et al. A mechanism of release of calreticulin from cells during apoptosis. J Mol Biol 2010;401: 799–812.
   PubMed Web of Science ®Google Scholar
• Van Wijk E, Krieger E, Kemperman MH, et al. A mutation in the gamma actin 1 (ACTG1) gene causes autosomal dominant hearing loss (DFNA20/26). J Med Genet 2003;40:879–884.
   PubMed Web of Science ®Google Scholar
• Sonnemann KJ, Fitzsimons DP, Patel JR, et al. Cytoplasmic γ-actin is not required for skeletal muscle development but its absence leads to a progressive myopathy. Dev Cell 2006;11:387–397.
   PubMed Web of Science ®Google Scholar
• Dammeyer P, Damdimopoulos AE, Nordman T, et al. Induction of cell membrane protrusions by the N-terminal glutaredoxin domain of a rare splice variant of human thioredoxin reductase 1. J Biol Chem 2008;283:2814–2821.
   PubMed Web of Science ®Google Scholar
• Bischoff FR, Krebber H, Kempf T, et al. Human RanGTPase-activating protein RanGAP1 is a homologue of yeast Rna1p involved in mRNA processing and transport. Proc Natl Acad Sci USA 1995;92: 1749–1753.
   PubMed Web of Science ®Google Scholar
• Kalab P, Pu RT, Dasso M. The ran GTPase regulates mitotic spindle assembly. Curr Biol 1999;9:481–484.
   PubMed Web of Science ®Google Scholar
• Nishimoto T. A new role of ran GTPase. Biochem Biophys Res Commun 1999;262:571–574.
   PubMed Web of Science ®Google Scholar
• Antonucci F, Chilosi M, Parolini C, et al. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 2003; 24:2376–2385.
   PubMed Web of Science ®Google Scholar
• Jeha S, Luo XN, Beran M, et al. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996;56:1445–1450.
   PubMed Web of Science ®Google Scholar
• Gez S, Crossett B, Christopherson RI. Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. Biochim Biophys Acta 2007; 1774:1173–1183.
   PubMed Web of Science ®Google Scholar
• Scherle P, Behrens T, Staudt LM. Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA 1993;90:7568–7572.
   PubMed Web of Science ®Google Scholar
• Scheffzek K, Stephan I, Jensen ON, et al. The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI. Nat Struct Biol 2000;7:122–126.
   PubMedGoogle Scholar
• Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signaling. Cell Signal 1999;11:545–554.
   PubMed Web of Science ®Google Scholar
• Bilodeau D, Lamy S, Desrosiers RR, et al. Regulation of Rho protein binding to membranes by rhoGDI: inhibition of releasing activity by physiological ionic conditions. Biochem Cell Biol 1999;77:59–69.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang Y, Dagher MC, et al. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 2005;65:6054–6062.
   PubMed Web of Science ®Google Scholar
• Kovarova H, Hajduch M, Korinkova G, et al. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis 2000;21:3757–3764.
   PubMed Web of Science ®Google Scholar
• Wan J, Wang J, Cheng H, et al. Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells. Electrophoresis 2001;22:3026–3037.
   PubMed Web of Science ®Google Scholar
• Wu X, Sooman L, Wickström M, et al. Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in Vitro. Mol Cancer Ther 2013;12:1526–1536.
   PubMed Web of Science ®Google Scholar
• Dantuma NP, Heinen C, Hoogstraten D. The ubiquitin receptor Rad23: at the crossroads of nucleotide excision repair and proteasomal degradation. DNA Repair (Amst) 2009;8:449–460.
   PubMed Web of Science ®Google Scholar
• Libri D, Mouly V, Lemonnier M, et al. A nonmuscle tropomyosin is encoded by the smooth/skeletal beta-tropomyosin gene and its RNA is transcribed from an internal promoter. J Biol Chem 1990; 265:3471–3473.
   PubMed Web of Science ®Google Scholar